Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

Exact Sciences at DDW 2022

SAN DIEGO and MADISON, Wis. – May 19, 2022 – Exact Sciences Corp., a leader in advanced cancer diagnostics, today announced its research collaborator will give an oral presentation detailing the consistently high performance of its multi-target hepatocellular carcinoma blood test (mt-HBT) across disease etiologies at the 2022 Digestive Disease Week conference in San Diego on May 22, 2022 at 4:00 p.m. PDT.

DDW SESSION DETAILS

Session Type: Research Forum 

Session Title: Prevention and Early Detection of Hepatocellular Carcinoma: An  Ounce of Prevention Better Than a Pound of Cure 

Date & Time: May 22, 2022 from 4:00 p.m. to 5:30 p.m. PDT (UTC –7)

Presentation Time: 4:00 p.m. to 4:15 p.m. PDT (UTC –7)

Presentation Title: The Multi-Target Hepatocellular Carcinoma Blood Test Provides High Sensitivity for Detecting Early-Stage Hepatocellular Carcinoma Across Important Patient Subgroups

Commercially known as the Oncoguard® Liver test, mt-HBT is designed for accurate early-stage detection in real-world settings. It measures DNA methylation markers and a protein marker through a routine blood draw to detect hepatocellular carcinoma (HCC), the leading form of liver cancer.

There is an unmet need for HCC testing. An estimated 3 million[i] Americans are eligible, but less than one in three[ii] at-risk patients receive recommended testing. Early-stage detection can increase five-year survival rates for HCC from less than 12%[iii], [iv] to upwards of 70%.[v]

Clinical validation data published last year in the journal Clinical Gastroenterology and Hepatology (CGH) show the Oncoguard® Liver test delivers 82% early-stage sensitivity[vi] for HCC detection, performance significantly higher than the current blood-based test included in guidelines.

The data to be presented at DDW analyzes subgroups from large multi-center patient cohorts reported in the CGH publication. This analysis further demonstrates the Oncoguard® Liver test’s consistently high sensitivity for early-stage HCC detection across patient subgroups and all tumor sizes.

The presentation will be led by investigator Dr. Amit Singal, Chief of Hepatology, Professor of Internal Medicine, Department of Internal Medicine and Population and Data Sciences, University of Texas-Southwestern in Dallas.

Visit Exact Sciences at Booth #925

A leader in cancer screening and diagnostic tests, Exact Sciences is working to support patients and providers at every step – before, during and after a cancer diagnosis. Conference attendees are invited to learn more about Exact Sciences and its Cologuard®, Oncotype®, and Oncoguard® Liver products at Booth #925 in the DDW expo hall.

 

###

 

 


 

 

[i] 3M U.S. patients calculated using Census Bureau estimates of population and prevalence of cirrhosis as reported in Beste et al., Gastroenterology (2015).

[ii] Singal AG et al., J Hepatology (2020).

[ii] National Cancer Institute. Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. 2021. https://seer.cancer.gov/statfacts/html/livibd.html   

[iv] Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450-1462.

[v] Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology.2018;154(6):1706-1718.e1. doi:10.1053/j.gastro.2018.01.064

[vi] Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ, Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma, Clinical Gastroenterology and Hepatology (2021), doi: https:// doi.org/10.1016/j.cgh.2021.08.010.  

Subscribe To The Blog